COMPPARE Newsroom Prostate cancer research news
The latest information for patients.
prostate Cancer News from around the world
Health News from The NIH
Designing a new antibiotic to combat drug resistance
Researchers designed a synthetic drug that shuts down protein production in a range of different bacteria.
How excess niacin may promote cardiovascular disease
Findings about a metabolite of niacin, or vitamin B3, raise concerns about the health effects of too much niacin and suggest new measures to help prevent or treat cardiovascular disease
Talk therapy cuts risk of postpartum depression
An intervention given to pregnant women by non-specialist providers greatly reduced the chances of developing postpartum depression or anxiety.
Insight into mechanisms of ME/CFS
Researchers compared people with post-infectious ME/CFS to those without and found important differences in their brains and other body systems.
Health News from UFHPTI
Choosing the right cancer treatment center
When faced with a cancer diagnosis, finding cancer care that is the best becomes a top-priority for individuals and their loved ones.
Advances in lung cancer treatment: the power of five radiation treatments
In the realm of oncology, treating lung cancer has long been a complex challenge due to the delicate nature of the surrounding structures and the potential for collateral damage.
What are the side effects of proton beam therapy?
When faced with a cancer diagnosis, the impact on one’s health and well-being become a paramount concern.
Navigating radiation therapy: a prostate cancer treatment guide
Receiving a prostate cancer diagnosis can be overwhelming, and understanding treatment options is crucial for making informed decisions.
News from COMPPARE
New Patient Surveys to Assist in Designing the…
In early June, COMPPARE Coordinators administered over 500 surveys to participants. The purpose of the surveys is to guide the design of the next…
What’s Next for COMPPARE?
Patient accrual has closed. Now, it’s up to participants to continue to complete COMPPARE’s Quality of Life and Side Effects Follow-up…
COMPPARE Completes Patient Enrollment
After four years and 2,524 enrolled patients, the COMPPARE team officially closed patient accrual to the study on October 31, 2022 at 11:59 p.m…